» Articles » PMID: 39200092

Early Cerebral Microvasculature Impairment and Increased Body Mass Index in Patients with Psoriasis

Overview
Journal Biomedicines
Date 2024 Aug 29
PMID 39200092
Authors
Affiliations
Soon will be listed here.
Abstract

Psoriasis induces systemic atherosclerosis, but its impact on cerebrovascular function remains unclear. However, stroke prevention must be considered in psoriasis, as it is commonly comorbid with classic cardiovascular risk factors. Thus, the aim of the study is to assess cerebral microvasculature function and its confounders in patients with psoriasis. The study protocol included cerebral autoregulation assessment with measurements of vasomotor reactivity reserve (VMRr) on the middle cerebral arteries with the use of a Transcranial Doppler (TCD) in 50 patients with psoriasis without cerebrovascular events (46; 21-74 years) and 26 healthy controls (41; 29-58 years). Analyses of VMRr relationships with the psoriasis course, comorbidities, inflammatory markers and intima-media thickness (IMT) were performed. The study showed that VMRr was lower (64% vs. 76%, = 0.001), and the IMT was higher (0.65 vs. 0.52 mm, = 0.001) in patients compared to controls. The patients were also characterized by a higher body mass index (BMI) and a higher level of Il-6 than the controls (29.14 vs. 25.76 kg/m, = 0.004 and 585 vs. 204 pg/mL, < 0.001, respectively), but only BMI was independently impacting VMRr reduction ( = 0.02). In conclusion, early cerebral microvasculature dysfunction may occur in patients with psoriasis, and its extent is associated with an increase in BMI. Thus, body mass reduction should be strongly recommended for stroke prophylaxis in patients with psoriasis.

References
1.
. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(10159):1736-1788. PMC: 6227606. DOI: 10.1016/S0140-6736(18)32203-7. View

2.
Settakis G, Pall D, Molnar C, Bereczki D, Csiba L, Fulesdi B . Cerebrovascular reactivity in hypertensive and healthy adolescents: TCD with vasodilatory challenge. J Neuroimaging. 2003; 13(2):106-12. View

3.
Armstrong A, Harskamp C, Armstrong E . Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol. 2013; 68(4):654-662. DOI: 10.1016/j.jaad.2012.08.015. View

4.
Armstrong A, Harskamp C, Armstrong E . The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies. J Hypertens. 2012; 31(3):433-42. DOI: 10.1097/HJH.0b013e32835bcce1. View

5.
Schafer I, Hacker J, Rustenbach S, Radtke M, Franzke N, Augustin M . Concordance of the Psoriasis Area and Severity Index (PASI) and patient-reported outcomes in psoriasis treatment. Eur J Dermatol. 2009; 20(1):62-7. DOI: 10.1684/ejd.2010.0815. View